TSHR; | |
FFAR1; FFAR4; | |
HDAC3; | |
ACHE; GAA; | |
FAAH; TDP1; TERT; HPGD; CBR1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; | |
TRPA1; | |
MAPK1; CDK6; | |
CA2; CA12; CA1; CA9; CA7; CA4; | |
PPARA; PPARD; PPARG; | |
ESR1; ESR2; | |
NR1I2; | |
KDM4E; | |
PTGS1; XDH; | |
TLR2; | |
HIF1A; TP53; | |
SLC22A8; SLC22A6; | |
ABCG2; | |
LMNA; NPC1; FABP3; FABP5; FABP2; FABP4; MAPT; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.974E-12 | 3.070E-09 | CA1, CA12, CA2, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.872E-11 | 4.015E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.263E-11 | 4.220E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.212E-10 | 1.055E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, NR1I2 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.721E-10 | 4.721E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.338E-10 | 4.993E-07 | CA1, CA12, CA2, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.785E-10 | 5.797E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.613E-09 | 1.459E-06 | CA1, CA12, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.796E-09 | 1.522E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, PTGS1 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.053E-09 | 1.622E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.027E-09 | 2.424E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 2.977E-08 | 9.972E-06 | AKR1B1, CA2, CA9, CYP1A2, ESR1, FABP3, FFAR4, HPGD, NPC1, PPARA, PPARG, TLR2, TSHR |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.720E-08 | 2.498E-05 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.331E-07 | 8.635E-05 | CA1, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG, TP53 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 7.117E-07 | 1.722E-04 | FABP2, FABP3, FABP4, FABP5 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 9.417E-07 | 2.182E-04 | CA2, CA4, CA9, HPGD, SLC22A6, SLC22A8, TSHR |
BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 1.827E-06 | 3.833E-04 | AKR1B1, CYP1A1, CYP1B1, HPGD, MAPK1, SLC22A8, TLR2, TP53, TRPA1 |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.831E-06 | 3.833E-04 | ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
CC | GO:0043226; organelle | GO:0043227; membrane-bounded organelle | 4.153E-06 | 8.147E-04 | ABCG2, ACHE, AKR1B1, ALDH1A1, CA1, CA2, CA4, CBR1, CDK6, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, ESR1, ESR2, FABP3, FABP4, FABP5, FFAR4, GAA, HDAC3, HIF1A, HPGD, HSD17B10, KDM4E, LMNA, MAPK1, MAPT, NPC1, PPARA, PPARD, PPARG, PTGS1, SLC22A6, SLC22A8, SMN1, SMN2, TDP1, TERT, TLR2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.719E-06 | 9.175E-04 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 6.089E-06 | 1.154E-03 | AKR1B1, FABP3, FFAR4, PPARA, PPARG, TLR2, TP53, TSHR |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 6.095E-06 | 1.154E-03 | ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 7.961E-06 | 1.494E-03 | ESR1, ESR2 |
CC | GO:0044464; cell part | GO:0044444; cytoplasmic part | 9.693E-06 | 1.716E-03 | ABCG2, ACHE, AKR1B1, ALDH1A1, ALOX15, CA1, CA2, CA4, CA7, CBR1, CDK6, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, ESR1, ESR2, FAAH, FABP2, FABP3, FABP4, FABP5, FFAR4, GAA, HDAC3, HIF1A, HPGD, HSD17B10, LMNA, MAPK1, MAPT, NPC1, PPARG, PTGS1, SMN1, SMN2, TERT, TLR2, TP53, XDH |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.018E-05 | 1.788E-03 | ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.154E-05 | 2.002E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.444E-05 | 2.400E-03 | CYP1A1, PPARD, PPARG |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.880E-05 | 2.945E-03 | CYP19A1, FFAR4, PPARA, PPARD, PPARG |
BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 1.936E-05 | 3.010E-03 | CYP1A2, MAPK1, NPC1, TERT |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.384E-05 | 3.655E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.384E-05 | 3.655E-03 | CYP1A1, CYP3A4 |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 2.406E-05 | 3.664E-03 | ESR1, PPARA, TERT |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.802E-05 | 4.067E-03 | CYP1A1, PPARG, TP53 |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 3.237E-05 | 4.638E-03 | HIF1A, TERT, TP53 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.421E-05 | 4.810E-03 | ABCG2, ACHE, ESR1, ESR2, HPGD, MAPK1, MAPT, PPARG, SLC22A6, SMN1, SMN2, TERT, TP53, TRPA1, XDH |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.716E-05 | 5.153E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 3.947E-05 | 5.376E-03 | FABP3, PPARA, PPARD, PPARG |
CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 3.947E-05 | 5.376E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 4.238E-05 | 5.593E-03 | CYP1A1, CYP1A2, PPARG |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.759E-05 | 6.096E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.759E-05 | 6.096E-03 | ESR1, ESR2 |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 4.806E-05 | 6.120E-03 | HIF1A, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 5.422E-05 | 6.824E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 5.534E-05 | 6.925E-03 | CA2, ESR1, MAPK1, PPARG |
BP | GO:0009987; cellular process | GO:0042981; regulation of apoptotic process | 6.122E-05 | 7.489E-03 | AKR1B1, CYP1B1, ESR1, FFAR4, HDAC3, HIF1A, HPGD, LMNA, MAPT, PPARD, PPARG, TERT, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 6.804E-05 | 8.074E-03 | CYP19A1, CYP3A4, ESR1 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 6.823E-05 | 8.074E-03 | ALOX15, PPARA, PPARD, TP53 |
BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 7.917E-05 | 9.081E-03 | PPARA, PPARG |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 7.923E-05 | 9.081E-03 | FABP3, FFAR1, PPARG, TLR2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 7.917E-05 | 9.081E-03 | CYP1A1, CYP3A4 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.947E-12 | 5.999E-10 | CA12; CA1; CA2; CA4; CA7; CA9 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 7.575E-10 | 5.757E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.597E-09 | 1.316E-07 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.826E-08 | 1.467E-06 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.474E-08 | 5.602E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.499E-07 | 1.628E-05 | CYP2C9; CBR1; ALOX15; CYP2C19; PTGS1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.355E-07 | 1.357E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.507E-06 | 7.612E-05 | CBR1; GAA; ALOX15; AKR1B1; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C9; CYP1A2; ALDH1A1; CYP1A1; XDH |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.513E-07 | 1.807E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.401E-05 | 2.129E-04 | CYP2C9; ALOX15; MAPK1; CYP2C19; PTGS1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.804E-05 | 2.493E-04 | HDAC3; MAPK1; TP53; ESR1; HIF1A |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.875E-05 | 4.908E-04 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.337E-05 | 5.071E-04 | CA2; SLC22A8; CYP3A4; ABCG2 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.363E-04 | 2.112E-03 | MAPK1; TP53; HIF1A; ESR1; TLR2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.513E-04 | 5.035E-03 | CDK6; MAPK1; PPARG; HIF1A; TP53; PPARD |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 6.962E-04 | 5.035E-03 | CDK6; MAPK1; TP53; TLR2 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.920E-04 | 3.739E-03 | CDK6; MAPK1; TP53 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 6.835E-05 | 7.421E-04 | MAPK1; PPARG; TP53 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.809E-04 | 1.719E-03 | CYP1A2; CYP1A1; CYP1B1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.520E-04 | 2.972E-03 | CYP1A1; CYP1B1; CYP19A1 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 7.619E-04 | 5.035E-03 | CDK6; MAPK1; TP53 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.920E-04 | 3.739E-03 | FABP4; TSHR; PTGS1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.966E-04 | 5.045E-03 | CDK6; MAPK1; TP53 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 9.853E-04 | 5.760E-03 | CDK6; MAPK1; TP53 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.026E-03 | 5.777E-03 | MAPK1; ESR1; ESR2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.323E-04 | 5.060E-03 | MAPK1; TP53; HIF1A |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.430E-03 | 1.231E-02 | CDK6; HDAC3; MAPK1; TP53 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.068E-03 | 5.798E-03 | CDK6; MAPK1; TP53 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.561E-03 | 1.256E-02 | MAPK1; ESR1; ESR2 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.753E-03 | 2.851E-02 | LMNA; MAPK1; TP53 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.861E-03 | 2.620E-02 | MAPK1; PPARA; TP53 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 6.234E-03 | 2.707E-02 | CDK6; TP53; TLR2 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.974E-03 | 3.514E-02 | CDK6; CYP1B1; MAPK1; TP53 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.431E-02 | 4.730E-02 | CDK6; MAPK1; TP53; TLR2 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.110E-02 | 4.114E-02 | MAPK1; MAPT; HSD17B10 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.335E-02 | 4.613E-02 | HPGD; PPARG; TP53 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.076E-02 | 4.088E-02 | MAPK1; PPARD |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.187E-02 | 4.295E-02 | MAPK1; HIF1A |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.016E-03 | 3.514E-02 | MAPK1; TP53 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.264E-02 | 4.466E-02 | MAPK1; TP53 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.423E-02 | 4.730E-02 | MAPK1; HIF1A |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.684E-03 | 2.618E-02 | MAPK1; TP53 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 7.112E-03 | 2.922E-02 | CYP3A4; XDH |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.074E-03 | 1.460E-02 | GAA; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.810E-03 | 9.488E-03 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.386E-05 | 7.485E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; TLR2 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; FAAH |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9; MAPK1; TLR2 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; NR1I2 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ACHE |
J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; CA9; MAPK1; ESR1; ESR1; TLR2; ACHE |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
NA: NA | Rheumatold arthritis | NA | PTGS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; ESR1; ESR1; TERT |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TERT |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; TRPA1; ACHE; FAAH; PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAPT; PPARG; PPARG |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; TLR2; TERT |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; PTGS1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
NA: NA | Upper abdominal bloating | NA | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PPARG |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
C00-D49: Neoplasms | Liver cancer | C22 | TERT |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
NA: NA | Menopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; PPARG |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
NA: NA | Dyslipidemia | NA | PPARD |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS1 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |